Does Amerigroup Cover Viagra? A Complete Coverage Guide

What Is Amerigroup and What Plans Does It Offer?

Amerigroup, now operating under the Anthem/Elevance Health umbrella, is a managed care organization that administers Medicaid, Medicare Advantage, and dual-eligible (Medicare-Medicaid) plans across roughly 19 states. The plan type you hold determines almost everything about Viagra coverage.

Medicaid Managed Care Plans

Most Amerigroup enrollees are in state Medicaid managed care programs. These plans must follow both federal Medicaid drug exclusions and any additional state-level restrictions. Federal law under Section 1927(d)(2) of the Social Security Act explicitly allows states to exclude drugs used for sexual or erectile dysfunction from Medicaid formularies, and most states exercise that exclusion for brand-name Viagra. The Centers for Medicare and Medicaid Services has confirmed this exclusion in its pharmacy guidance.

Medicare Advantage Plans

Amerigroup also offers Medicare Advantage (Part C) plans that bundle Part D prescription drug coverage. Unlike traditional Medicaid, Medicare Advantage Part D plans are not subject to the same categorical ED drug exclusion. The Affordable Care Act and subsequent CMS guidance gave Part D sponsors discretion to include ED drugs on their formularies. Whether a specific Amerigroup MA plan covers sildenafil depends on that plan's annual formulary, which CMS requires to be posted publicly each year. CMS Part D formulary requirements are described here.

Dual-Eligible Special Needs Plans

Members enrolled in Amerigroup D-SNPs (Dual Special Needs Plans) receive benefits from both Medicaid and Medicare. Drug coverage for these members typically follows Medicare Part D rules, meaning ED drug coverage is plan-specific rather than categorically excluded.

The Federal Rule That Blocks Most Medicaid Viagra Coverage

The core reason Amerigroup Medicaid does not cover Viagra is federal statute, not plan preference. Section 1927(d)(2)(K) of the Social Security Act permits states to exclude from their Medicaid formularies any drug used to treat sexual or erectile dysfunction. The vast majority of states have adopted this exclusion. The statutory text and CMS interpretation are available through the Social Security Administration.

What This Means in Practice

Brand-name Viagra (sildenafil 25 mg, 50 mg, 100 mg indicated for ED) is almost universally excluded from state Medicaid formularies. The National Conference of State Legislatures documented that fewer than five states have passed legislation to restore partial ED drug coverage under Medicaid, and none provide comprehensive brand-name Viagra coverage without significant restrictions. NCBI analysis of Medicaid formulary exclusions supports this pattern.

Generic Sildenafil Is Not Automatically Exempt

Some members assume that because generic sildenafil is inexpensive, Medicaid would simply cover it. The exclusion applies to the drug's indication, not its brand status. Generic sildenafil prescribed specifically for ED carries the same exclusion as brand Viagra. This distinction matters when a provider writes the prescription: the documented diagnosis code determines whether coverage applies.

The Pulmonary Arterial Hypertension Exception

Sildenafil is FDA-approved for two distinct indications. The ED indication uses the trade name Viagra. The pulmonary arterial hypertension indication uses the trade name Revatio (sildenafil 20 mg three times daily). Because PAH is not a sexual dysfunction condition, the federal exclusion does not apply to Revatio-indicated sildenafil.

How PAH Coverage Works Under Amerigroup

When a prescriber documents a diagnosis of pulmonary arterial hypertension (ICD-10 code I27.0) and prescribes sildenafil 20 mg three times daily, that prescription may qualify for Medicaid coverage even under Amerigroup plans that exclude Viagra. The FDA's original approval of Revatio for PAH is documented here.

A 2013 randomized trial (SUPER-1, N=278) showed sildenafil 20 mg three times daily reduced pulmonary vascular resistance by 28% at 12 weeks compared with placebo (P<0.001). The trial findings appear in the NEJM supplementary database. Because this evidence base is strong, plans including Amerigroup Medicaid typically maintain sildenafil on formulary under the PAH benefit, often in a Tier 2 or Tier 3 position requiring prior authorization.

The Off-Label Gray Zone

Some physicians have prescribed sildenafil 20 mg at higher frequencies to effectively treat ED while coding PAH. This practice is fraudulent if the patient does not genuinely have PAH and exposes both the prescriber and the patient to recoupment actions. Amerigroup conducts retrospective claims audits; diagnosis-drug mismatches trigger medical record requests.

Does Any Part of Amerigroup Cover Viagra for ED?

The short answer: possibly, under Medicare Advantage Part D plans. The longer answer requires checking the specific plan year's formulary.

Checking the Amerigroup Medicare Advantage Formulary

CMS requires every Medicare Advantage-PD plan to publish its formulary in a standardized format. You can search the Medicare Plan Finder at medicare.gov or request the Evidence of Coverage document directly from Amerigroup member services. Look for sildenafil under the brand entry "Viagra" or the generic entry "sildenafil citrate" in the formulary's sexual dysfunction drug category.

If sildenafil appears on the formulary, note its tier (Tier 3 or Tier 4 are common for specialty generics), whether step therapy applies, and whether prior authorization is required. CMS guidance on Medicare Part D coverage determinations is published here.

State-Specific Variations for Medicaid

A handful of states have enacted legislation or issued state plan amendments that partially restore ED drug coverage under Medicaid. As of 2024, the states with any documented ED drug coverage carve-in under Medicaid managed care are extremely limited. State Medicaid pharmacy policy variations are tracked by the Kaiser Family Foundation. If you live in one of those states and are enrolled in Amerigroup Medicaid, your plan's state-specific formulary may differ from the national default.

Prior Authorization: What Amerigroup Requires

Even when coverage exists, sildenafil almost always requires prior authorization (PA) from Amerigroup before the pharmacy will dispense it at plan cost. PA denials are common on first submission, but they are not final.

Standard PA Criteria for Sildenafil

Amerigroup PA criteria for sildenafil typically include:

• A documented diagnosis consistent with the covered indication (PAH for Medicaid; ED or PAH for eligible MA plans)
• Prescriber attestation that the patient has tried and failed, or is contraindicated for, alternative therapies where applicable
• Laboratory or diagnostic workup supporting the diagnosis (echocardiogram and right heart catheterization for PAH)
• Quantity limits: most plans restrict ED-indicated sildenafil to six doses per 30 days under Medicare Part D

CMS prior authorization rules for Medicare Advantage are codified in 42 CFR Part 422.

Submitting a PA Request

The prescribing provider submits the PA request, not the patient. The Amerigroup fax number and online portal for PA submissions appear on the back of your member ID card. Federal law under the Consolidated Appropriations Act of 2021 requires Medicare Advantage plans to respond to urgent PA requests within 72 hours and standard requests within 7 calendar days. CMS summarizes these timelines here.

How to Appeal a Coverage Denial

A denial is not the end of the road. Amerigroup must follow CMS-mandated appeals processes. The denial letter itself must state the reason for denial and provide appeal instructions.

Step 1: Request a Formulary Exception or Coverage Determination

If sildenafil is not on the formulary, your prescriber can request a formulary exception by documenting medical necessity. CMS coverage determination rules under Medicare Part D give enrollees the right to request a formulary exception. The prescriber must submit clinical documentation showing why the excluded drug is medically necessary and why on-formulary alternatives are clinically inappropriate.

Step 2: File a First-Level Appeal

If the initial PA or formulary exception request is denied, file a first-level appeal within 60 days of the denial notice for Medicare plans. A 2018 HHS Office of Inspector General report found that Medicare Advantage organizations overturned approximately 75% of denied claims that reached an internal appeal. The OIG report is available here.

Step 3: External Independent Review

If the internal appeal fails, you may request review by an Independent Review Entity (IRE). For Medicaid managed care appeals, state-level fair hearing rights apply. Medicaid managed care appeals rights are described under 42 CFR 438.400.

Step 4: State Insurance Commissioner Complaint

Filing a complaint with your state's insurance commissioner or Medicaid agency is a parallel option. Amerigroup, as a licensed managed care organization, is subject to state insurance department oversight and must respond to formal complaints within defined timeframes.

What Amerigroup Members Actually Pay for Sildenafil Out of Pocket

When coverage is denied or not applicable, out-of-pocket costs matter. Brand Viagra retails at approximately $70, $85 per tablet without insurance, making a monthly supply prohibitively expensive. Generic sildenafil changes the math significantly.

Generic Sildenafil Pricing in 2024

As of 2024, generic sildenafil 50 mg (30 tablets) costs approximately $25, $60 at major retail pharmacies using GoodRx-type coupons. Some pharmacies, including Mark Cuban's Cost Plus Drugs (costplusdrugs.com), list sildenafil 50 mg at under $1 per tablet. FDA approval of generic sildenafil is documented here.

Manufacturer Patient Assistance Programs

Pfizer historically offered a patient assistance program for Viagra. Generic competition has largely made this less relevant, but programs like NeedyMeds and RxAssist maintain databases of current manufacturer assistance programs. These are distinct from insurance coverage and do not require Amerigroup approval.

Erectile Dysfunction: Clinical Background

Understanding the clinical evidence base for ED treatment helps contextualize why coverage decisions matter. ED affects an estimated 30 million men in the United States, with prevalence rising sharply with age. CDC data on ED prevalence are referenced here.

Sildenafil Mechanism and Efficacy

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor. It works by increasing cyclic GMP in smooth muscle, promoting vasodilation in penile tissue. The original Phase III trial data supporting FDA approval, published in the NEJM, showed sildenafil improved erections in 69% of men versus 22% on placebo.

A 2018 Cochrane systematic review of 82 randomized trials (N=8,966) confirmed that sildenafil significantly improved the International Index of Erectile Function (IIEF) score versus placebo, with a standardized mean difference of 0.84 (95% CI 0.74 to 0.94). The Cochrane review is accessible here.

Safety Profile and Contraindications

Sildenafil is contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate) due to risk of severe hypotension. This contraindication is absolute. The American Urological Association guideline on ED (2018, updated 2024) states: "PDE5 inhibitors are the preferred first-line pharmacotherapy for erectile dysfunction in men without contraindications." The AUA guideline is available through the AUA website.

Men on alpha-blockers require dose separation of at least four hours when taking sildenafil. Common side effects include headache (16%), flushing (10%), and dyspepsia (7%) based on pooled trial data. FDA prescribing information for sildenafil summarizes safety data here.

Cardiovascular Comorbidity and ED

ED is frequently a marker for underlying cardiovascular disease. The Princeton Consensus III guidelines recommend cardiovascular risk stratification before initiating PDE5 inhibitor therapy. Men classified as high cardiac risk should undergo cardiology evaluation before receiving sildenafil. The Princeton III consensus statement was published in the American Journal of Cardiology. This clinical complexity is one reason plans require PA: a prescriber must confirm the patient has been appropriately evaluated.

Alternative PDE5 Inhibitors and Their Amerigroup Coverage

Sildenafil is not the only PDE5 inhibitor. Tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) are FDA-approved alternatives. Coverage patterns differ.

Tadalafil (Cialis / Generic)

Generic tadalafil became available in the United States in 2018. Its pricing is similar to generic sildenafil, approximately $15, $50 per month. Under Amerigroup Medicaid, tadalafil for ED faces the same federal exclusion as sildenafil. However, tadalafil is also FDA-approved for benign prostatic hyperplasia (BPH, ICD-10 N40.1) at a dose of 5 mg daily. FDA approval of tadalafil for BPH is documented here. When prescribed for BPH, the exclusion may not apply, and some Amerigroup Medicaid plans do cover low-dose daily tadalafil for BPH on their formularies.

Vardenafil and Avanafil

Vardenafil and avanafil remain available primarily as brand products with limited generic availability. Neither has a secondary non-ED indication that exempts them from the Medicaid exclusion. Costs without coverage can exceed $400 per month for brand products.

HealthRX Coverage Decision Framework for Amerigroup Members

When a patient asks whether Amerigroup will cover their ED medication, the clinical team at HealthRX applies the following decision pathway:

1. Identify plan type: Medicaid managed care, Medicare Advantage Part D, or D-SNP.
2. For Medicaid: Check whether the state has a carve-in for ED drugs. If not, assess whether a non-ED indication (PAH for sildenafil, BPH for tadalafil) is clinically documented and appropriate.
3. For Medicare Advantage: Pull the current year's formulary directly from the CMS plan finder. Identify tier, PA requirements, and quantity limits.
4. For any plan: Submit PA with complete diagnostic documentation before dispensing. Build in the appeal timeline if the initial PA is denied.
5. Regardless of coverage outcome, provide the patient with out-of-pocket generic pricing at Cost Plus Drugs or GoodRx to ensure medication access is not delayed while the PA process runs.

This framework reduces unnecessary coverage delays and ensures members do not go without treatment while administrative processes proceed.

What Your Doctor Should Document

The quality of clinical documentation in the PA request is the single biggest determinant of approval. Prescribers submitting to Amerigroup should include:

• The specific diagnosis code (I27.0 for PAH, N40.1 for BPH, N52.9 for ED when applicable)
• A brief clinical summary explaining why the requested drug is medically necessary
• Documentation of any contraindications to alternatives
• Relevant lab values, imaging, or specialist notes

The American College of Physicians has published guidance on reducing unnecessary prior authorization burdens, noting that "PA requirements for medications with strong evidence bases frequently delay care without improving outcomes." The ACP position statement is available here. This perspective supports aggressive pursuit of appeals when initial PA is denied.

Special Populations: What Changes Coverage Eligibility

Men With Diabetes

Diabetes is among the strongest risk factors for ED, affecting approximately 35 to 75% of men with the condition. A systematic review in Diabetic Medicine (N=6,199) found an odds ratio of 3.5 for ED in men with type 2 diabetes versus controls. Despite this prevalence, the Medicaid ED drug exclusion applies equally to men with diabetes; the comorbidity does not create a coverage exception under current federal rules. However, documenting diabetes-related neuropathy and vascular disease as contributing factors may strengthen a PA submission or appeal for Medicare Advantage plans.

Men Post-Prostatectomy

ED following radical prostatectomy affects 40 to 80% of men depending on nerve-sparing technique. A pooled analysis of 18 trials (N=3,052) found PDE5 inhibitors modestly improved erectile function post-prostatectomy (IIEF improvement of 4.2 points versus 1.1 for placebo). Post-prostatectomy ED may qualify as a distinct clinical scenario in some Medicare Advantage PA criteria, and prescribers should reference the surgical history explicitly in the PA documentation.

Testosterone Deficiency and ED

Hypogonadism (low serum testosterone) is a recognized contributor to ED. Men with documented hypogonadism (total testosterone <300 ng/dL on two morning draws, per Endocrine Society guidelines) may benefit from testosterone replacement therapy (TRT) alongside or instead of PDE5 inhibitors. The Endocrine Society clinical practice guideline on testosterone therapy is published here. TRT coverage under Amerigroup plans follows a separate formulary pathway and generally has broader Medicaid coverage than ED-specific drugs, since hypogonadism is not classified as a sexual dysfunction condition for formulary exclusion purposes.

How to Contact Amerigroup About Coverage

Amerigroup member services can be reached at the number on the back of your member ID card. For pharmacy benefit questions specifically:

• Request the current plan formulary (also available on the Amerigroup member portal)
• Ask whether sildenafil appears on the formulary and under what diagnosis
• Ask what PA criteria apply and request the criteria document in writing (members have the right to receive this)
• Ask about the specific appeal rights and deadlines for your plan type

CMS guarantees these disclosure rights to Medicare beneficiaries under 42 CFR 422.111. Medicaid managed care enrollees have parallel rights under 42 CFR 438.10.